IHAM
NGNE icon

Integral Health Asset Management’s Neurogene NGNE Stock Holding History

Integral Health Asset Management’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-70,000
Closed -$2.94M – 91
2024
Q3 		$2.94M Hold
70,000
– – 0.33% 56
2024
Q2 		$2.55M Buy
+70,000
New +$2.47M 0.24% 69

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Integral Health Asset Management's NGNE Position: Q4 2024 in Review

Integral Health Asset Management sold out of Neurogene (NGNE) in Q4 2024, closing a stake of 70,000 shares — an estimated $2.94M sold.

Integral Health Asset Management first reported a position in NGNE in Q2 2024 and held it in 2 quarters. The position peaked at $2.94M in Q3 2024. 88 funds tracked by Wall St. Rank hold NGNE as of Q4 2024.

  • Integral Health Asset Management reported no remaining Neurogene position as of Q4 2024 after selling out during the quarter.
  • Integral Health Asset Management sold 70,000 Neurogene shares in Q4 2024, an estimated $2.94M.
  • Integral Health Asset Management first reported a position in Neurogene in Q2 2024 and held it in 2 quarters.
  • Integral Health Asset Management's Neurogene position peaked at $2.94M in Q3 2024.
  • 88 funds tracked by Wall St. Rank held Neurogene as of Q4 2024.

Based on Integral Health Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.